A stable saturation on day five of ECMO does not, by itself, show that an infant can tolerate stopping inhaled nitric oxide (iNO). The circuit may be supporting gas exchange while native lung function and pulmonary hypertension still need reassessment. In a short-answer question, treat improvement as a reason to evaluate readiness—not as a stop date.
The stem does not specify the current iNO dose, ECMO settings, native-lung oxygenation, or pulmonary-pressure trajectory. Don’t invent those details or declare the infant ready. Give a conditional protocol: if improvement is sustained and the team judges the infant ready, reduce iNO gradually, monitor each step, and reverse the last step if the infant deteriorates.
Separate iNO withdrawal from ECMO liberation
These are related but distinct decisions. ECMO can support oxygenation while native lung gas exchange remains inadequate; a reassuring SpO₂ while circuit support is unchanged cannot prove that iNO is no longer needed. Consider the clinical and hemodynamic course, native respiratory function, and—when useful—echocardiographic evidence about pulmonary pressures and right-ventricular function.
There is no single ECMO-specific iNO schedule used by every center. Some neonatal ECMO teams stop iNO after cannulation, occasionally immediately; others continue it selectively, including during recovery or trials off ECMO. These different practices do not establish one universal approach. Abrupt cessation can still cause rebound pulmonary hypertension, so distinguish a team’s individualized decision to stop iNO at cannulation from a planned taper of ongoing therapy. For an active wean, follow the local ECMO and iNO protocol, and keep changes in ECMO support visible when interpreting the infant’s response.
Write the protocol as four checkpoints
| Checkpoint | What to include in an SAQ | Reasoning trap to avoid |
|---|---|---|
| Readiness | Wait for sustained clinical improvement, stable hemodynamics, and an assessment of native pulmonary function and pulmonary-hypertension trajectory. | Treating five days of improvement or a stable SpO₂ on ECMO as sufficient proof of readiness. |
| Step-down | If the team elects to wean ongoing iNO, reduce it in steps. For an infant receiving 20 ppm, one common example is 20 → 10 → 5 ppm, then 1-ppm decrements toward discontinuation, observing the response at each step. | Treating one taper as an ECMO-specific schedule, or jumping from a high dose—or directly from 5 ppm—to off during a planned wean. |
| Monitoring | Track preductal SpO₂, PaO₂ when available, oxygen requirement, and hemodynamics alongside ventilator and ECMO support. | Attributing a stable saturation to lung recovery when circuit support has not changed. |
| If a step fails | Return to the prior effective dose or restart iNO if needed; reassess and retry only after the infant is stable. | Continuing a planned taper despite worsening oxygenation or circulation. |
For infants not on ECMO, a common readiness clue is sustained improvement with adequate oxygenation on reduced support; some neonatal pathways use FiO₂ below 0.60. Once iNO is down to 5 ppm, one published approach reduces by 1 ppm every 30 minutes to 2 hours while oxygenation remains adequate. These are examples, not a universal clock—and on ECMO, FiO₂ and SpO₂ must be interpreted in context rather than treated as independent proof of native recovery.
Some protocols use a fall of about 5 percentage points in preductal SpO₂ or an FiO₂ increase of about 0.10 (10 percentage points) as a reason to pause or reverse a reduction. Exact definitions and cutoffs vary, and they are not an ECMO-specific rule. If an exam stem names a protocol, use its thresholds; otherwise, state the principle clearly: assess every decrement and do not continue through deterioration.
Make the response to failure explicit
When an infant receiving ongoing iNO is being weaned, abrupt withdrawal can cause rebound pulmonary hypertension and worsening oxygenation. The board-relevant response is practical: restore the last effective iNO dose, reassess oxygenation and hemodynamics, and look for other changes that could explain the decline. Once stable, the team can consider another, slower attempt using its protocol.
Avoid turning a complex physiologic response into a single certain molecular explanation, such as claiming that rebound is simply caused by suppression of endogenous nitric oxide synthase. For this SAQ, recognizing the risk, describing a monitored stepwise wean when that is the chosen plan, and naming the rescue action matter more than asserting one mechanism.
A concise answer could read: After sustained improvement and hemodynamic stability, reassess whether native pulmonary function and pulmonary-hypertension status support an iNO wean. If the team elects to wean ongoing iNO, reduce the dose stepwise—for example, from 20 to 10 to 5 ppm, then by 1 ppm toward off—monitoring oxygenation and hemodynamics at each step. If the infant worsens, return to the previous effective dose and retry only after reassessment and stability; on ECMO, interpret saturation alongside circuit support and the local protocol.
A six-minute retrieval exercise
Close your notes. Set a six-minute timer and write four headings from memory: ready, reduce, monitor, rescue. Under each, add one sentence that would earn credit in an SAQ. Do not start by copying a dose ladder; first retrieve the sequence of decisions.
Now test the reasoning with two changes to the scenario:
- The SpO₂ remains stable, but ECMO support is unchanged. Can you conclude that the lungs have recovered enough to stop iNO? No—state what additional clinical, native-lung, or hemodynamic information you would assess.
- During a reduction from 5 to 4 ppm, preductal saturation falls by 6 percentage points or oxygen need rises substantially. What is your next step? Return to the prior effective dose, reassess, and defer another attempt until the infant is stable.
Finally, check your answer for four errors: calendar shortcut (day five means stop), circuit blind spot (stable saturation proves independence), abrupt withdrawal during a planned taper, and no rescue plan. Correct the missed line, then answer the original prompt once more without looking. That closed-note retrieval and correction tests whether you can produce a safe sequence—not just recognize familiar numbers.
Practical takeaways
- Improvement over five days prompts reassessment; it does not set an iNO stop date.
- If the team elects to wean ongoing iNO, give a stepwise taper and monitor each reduction; use the local ECMO-specific protocol rather than claiming one universal schedule.
- On ECMO, interpret oxygenation alongside circuit support, native lung function, and the hemodynamic course.
- If oxygenation or hemodynamics worsen, return to the prior effective dose, reassess, and retry only after stability.
